Table 4. Salvage radiation therapy for locoregional recurrence of extrahepatic bile duct cancer.
| Study | Year | No. | DFI > 1-year | CCRT | Maintenance CT | 2-yr LPFS | 2-yr PFS | 2-yr OS | Prognostic factor on OS |
|---|---|---|---|---|---|---|---|---|---|
| Kim et al. a | 2015 | 25 | 48% | 76% | 12% | 44% (14) | 15% (9) | 55% (24) | CCRT, CA19-9 |
| Kim et al. | 2017 | 23 | 43% | 78% | 30% | 54% (NA) | 49% (15) | 44% (18) | DFI, initial T-stage |
| Yu et al. a | 2017 | 42 | 37% | 100% | 29% | 34% (15) | 19% (10) | 56% (41) | concurrent CT regimen, CA 19–9, initial T-stage |
| Current study | 2021 | 76 | 49% | 80% | 32% | 61% (33)b | 25% (9) | 33% (16) | CCRT, RT dose, DFI |
Numbers in parenthesis are median values of the survival time (month).
aThese studies included patients with recurrent biliary tract cancer originating from other than extrahepatic bile duct: n = 3 (ampulla of vater) and n = 9 (ampulla of vater, gallbladder, and intrahepatic bile duct).
bFreedom from locoregional progression was evaluated in this current study.
DFI, disease-free interval; CCRT, concurrent chemoradiation therapy; CT, chemotherapy; LPFS, locoregional progression-free survival; PFS, progression-free survival; OS, overall survival; CA 19–9, Carbohydrate antigen 19–9; NA, not assessed; RT, radiation therapy.